JP2024543372A5 - - Google Patents

Info

Publication number
JP2024543372A5
JP2024543372A5 JP2024527320A JP2024527320A JP2024543372A5 JP 2024543372 A5 JP2024543372 A5 JP 2024543372A5 JP 2024527320 A JP2024527320 A JP 2024527320A JP 2024527320 A JP2024527320 A JP 2024527320A JP 2024543372 A5 JP2024543372 A5 JP 2024543372A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
independently
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079790 external-priority patent/WO2023086979A1/en
Publication of JP2024543372A publication Critical patent/JP2024543372A/ja
Publication of JP2024543372A5 publication Critical patent/JP2024543372A5/ja
Pending legal-status Critical Current

Links

JP2024527320A 2021-11-15 2022-11-14 ねじれ形3種脂質修飾核酸化合物 Pending JP2024543372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279270P 2021-11-15 2021-11-15
US63/279,270 2021-11-15
PCT/US2022/079790 WO2023086979A1 (en) 2021-11-15 2022-11-14 Staggered triple lipid-modified nucleic acid compounds

Publications (2)

Publication Number Publication Date
JP2024543372A JP2024543372A (ja) 2024-11-21
JP2024543372A5 true JP2024543372A5 (cg-RX-API-DMAC10.html) 2025-11-27

Family

ID=86336682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527320A Pending JP2024543372A (ja) 2021-11-15 2022-11-14 ねじれ形3種脂質修飾核酸化合物

Country Status (10)

Country Link
US (1) US20250027082A1 (cg-RX-API-DMAC10.html)
EP (1) EP4433064A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024543372A (cg-RX-API-DMAC10.html)
KR (1) KR20240103016A (cg-RX-API-DMAC10.html)
CN (1) CN118215484A (cg-RX-API-DMAC10.html)
AU (1) AU2022387688A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235447A1 (cg-RX-API-DMAC10.html)
IL (1) IL312217A (cg-RX-API-DMAC10.html)
MX (1) MX2024005742A (cg-RX-API-DMAC10.html)
WO (1) WO2023086979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026163078A1 (en) 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7583712B2 (ja) * 2018-05-30 2024-11-14 ノバルティス アーゲー 脂質修飾された核酸化合物および方法
JP2023503644A (ja) * 2019-11-27 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Similar Documents

Publication Publication Date Title
DE69925624T2 (de) Nukleinsäure-markierungsverbindungen
US7053199B2 (en) Nucleoside analogs and oligonucleotide derivatives containing these analogs
KR100571299B1 (ko) 펜토피라노실 뉴클레오시드 및 이의 제조방법
JP5520818B2 (ja) Rna合成のためのチオ炭素保護基
JP7748500B2 (ja) トリループを含む二本鎖核酸インヒビター分子
JP2023503722A5 (cg-RX-API-DMAC10.html)
JP2005519035A5 (cg-RX-API-DMAC10.html)
JP2024079716A5 (cg-RX-API-DMAC10.html)
JP2023503644A5 (cg-RX-API-DMAC10.html)
EP0741741B1 (en) Modified oligonucleotides
Pitsch An Efficient Synthesis of Enantiomeric Ribonucleic Acids from D‐Glucose
JPH08511002A (ja) ポリヌクレオチド架橋剤としての非ヌクレオシドクマリン誘導体
JP2019141097A5 (cg-RX-API-DMAC10.html)
CA2628883C (en) Novel 3'-modified oligonucleotide derivatives
TW202122093A (zh) 化合物、藥物綴合物、試劑盒及其用途
JP2008043341A (ja) 新規な塩基対形成スキームの使用による非特異的ハイブリダイゼーションの減少
PT98931B (pt) Processo para a ligacao de nucleosidos com uma ponte siloxano
US6326487B1 (en) 3 modified oligonucleotide derivatives
JP2022533419A5 (cg-RX-API-DMAC10.html)
JP2024544975A5 (cg-RX-API-DMAC10.html)
JP2023535730A5 (cg-RX-API-DMAC10.html)
JP2024536146A5 (cg-RX-API-DMAC10.html)
CN111971051A (zh) 用增加tm的核苷酸修饰的双链核酸抑制剂分子
PL192832B1 (pl) Pochodna 5'-dezoksy-cytydyny, sposób jej wytwarzania, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw
JP2022526267A5 (cg-RX-API-DMAC10.html)